Två genombrott i behandling av typ 2-diabetes. Både receptoragonist och enzymhämmare har nu nått kliniken.

Research output: Contribution to journalArticle

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Other Clinical Medicine

Keywords

  • Type 2: drug therapy, Enzyme Inhibitors: administration & dosage, Enzyme Inhibitors: therapeutic use, Glucagon-Like Peptide 1: metabolism, Hypoglycemic Agents: administration & dosage, Hypoglycemic Agents: therapeutic use, Nitriles: administration & dosage, Nitriles: therapeutic use, Peptides: administration & dosage, Peptides: therapeutic use, Pyrrolidines: administration & dosage, Pyrrolidines: therapeutic use, Receptors, Glucagon: drug effects, Venoms: therapeutic use, Venoms: administration & dosage, Diabetes Mellitus, CD26: antagonists & inhibitors, Antigens, Adamantane: therapeutic use, Adamantane: administration & dosage, Adamantane: analogs & derivatives
Original languageSwedish
Pages (from-to)3763-3764
JournalLäkartidningen
Volume104
Issue number49-50
Publication statusPublished - 2007
Publication categoryResearch
Peer-reviewedYes